Haematology Department, Imperial College, Hammersmith Hospital, 4th Floor Commonwealth Building, Du Cane Rd, London, W12 0NN, UK.
Int J Hematol. 2011 Mar;93(3):274-280. doi: 10.1007/s12185-011-0781-3. Epub 2011 Mar 8.
Despite recent advances in the treatment of leukemia, many patients will relapse and novel therapeutic strategies are therefore needed. The identification of a number of leukemia-associated antigen (LAA) and advances in understanding the fundamentals of tumor immunology have fostered the progress of both active (vaccines) and adoptive immunotherapy. Preliminary results from a number of studies suggest that vaccination using peptides derived from a number of LAA induce immune responses which may translate into clinical responses. These promising early results point the way to optimizing the administration of peptide vaccines. In this review, we will focus on the results of clinical trials of vaccination in leukemia and potential strategies to enhance the efficacy of immunotherapy in the future.
尽管白血病的治疗在最近取得了进展，但许多患者仍会复发，因此需要新的治疗策略。已经鉴定了许多白血病相关抗原 (LAA)，并且对肿瘤免疫学基础的理解也有了进展，这促进了主动（疫苗）和过继免疫疗法的发展。一些研究的初步结果表明，使用来自多种 LAA 的肽进行疫苗接种可诱导免疫反应，从而转化为临床反应。这些有希望的早期结果为优化肽疫苗的管理指明了方向。在这篇综述中，我们将重点介绍白血病疫苗接种临床试验的结果以及未来增强免疫疗法疗效的潜在策略。
